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ABSTRACT
3,5-Diaryl-4,5-dihydroisoxazoles were synthesized and evaluated as monoamine oxidase (MAO) enzyme
inhibitors and iron chelators. All compounds exhibited selective inhibitory activity towards the B isoform of
MAO in the nanomolar concentration range. The best performing compound was preliminarily evaluated
for its ability to bind iron II and III cations, indicating that neither iron II nor iron III is coordinated. The
best compounds racemic mixtures were separated and single enantiomers inhibitory activity evaluated.
Furthermore, none of the synthesised compounds exhibited activity towards MAO A. Overall, these data
support our hypothesis that 3,5-diaryl-4,5-dihydroisoxazoles are promising scaffolds for the design of neu-
roprotective agents.
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Introduction
Amine oxidase is a widely diffused family of enzymes responsible
for the oxidative deamination of both endogenous and exogenous
monoamines, diamines and polyamines. These enzymes are divided
into two classes, flavin adenine dinucleotide amino oxidase (FAD-
AO) (EC 1.4.3.4)1 and copper topaquinone amino oxidase (Cu/TPQ-
AO)2. The former, named monoamine oxidase (MAO), contains fla-
vin adenin dinucleotide (FAD) as a cofactor while the latter contains
2,4,5-trihydroxyphenylalanine quinone as cofactor (TPQ-Cu) and are
inhibited by semicarbazide. Regarding FAD-AO, two isoforms, MAO-
A and MAO-B, have been isolated, differing from central nervous
system (CNS) location, substrate specificity and sensitivity to inhibi-
tors3,4. MAO enzymes5 play a key role in the metabolism of mono-
amine neurotransmitters, and have been therefore studied in a
number of psychiatric and neurological diseases6. Moreover, the
MAO catalysed oxidative deamination of amines leads to the forma-
tion of hydrogen peroxide which is co-responsible for neurodegen-
eration7. Not surprisingly a number of MAO inhibitors have been
investigated as neuroprotective agents in the treatment of
Parkinson and Alzheimer diseases3,4,6,8–10. We have previously iden-
tified highly potent and selective MAO B inhibitors characterised by
a 3,5-diaryl-4,5-dihydro-(1H)-pyrazole scaffold11 and investigated on
the structural requirements for the enzyme inhibition (Figure 1). In
particular, the presence of two aryl substituents on the dihydro-
(1H)-pyrazole nucleus appeared as essential for MAO B selectivity
and inhibition potency activity12–15. Hence, we designed and
studied 2-thiazolylhydrazones derivatives, ideally originated by
removing C4 and C5 from the dihydropyrazole ring. These deriva-
tives exhibited high potency and selectivity towards MAO B16–19.
More recently, through the isosteric replacement of the carbon 4 of
the previously reported dihydropyrazole derivatives11 with an
oxygen atom, we have designed and synthesised two series of 2,3-
dihydro-oxadiazoles20–22 that exhibited high selectivity and activity
towards MAO B. Moreover, we observed that the introduction of a
3,4-dichlorophenyl substituent in the position 2 of the dihydro-oxa-
diazole core is crucial for both selectivity and potency21. According
to these structural information and with the aim of setting new hit
structures for MAO B inhibition, we have devised a synthetic path-
way to obtain 3,5-diaryl-4,5-dihydroisoxazoles as bio-isosters of




Starting materials and reagents were obtained from commercial
suppliers and were used without purification. All melting points
were determined on a Stuart SMP11 melting points apparatus and
are uncorrected (East Yorkshire, UK). Electron ionization mass spec-
tra were obtained by a Fisons QMD 1000 mass spectrometer
(70 eV, 200mA, ion source temperature 200 C) (Loughborough,
UK). Samples were directly introduced into the ion source. Found
mass values are in agreement with theoretical ones. Melting
points, yield of reactions and the analytical and descriptive data of
derivatives are reported in Table 1.
1H-NMR (Table 2) were registered on a Bruker AMX 300MHz
spectrometer (Billerica, MA). All samples were measured in CDCl3.
Chemical shifts are reported referenced to the solvent in which
they were measured. Coupling constants J are expressed in Hz.
Elemental analyses were obtained on a Perkin-Elmer 240 B micro-
analyser (Waltham, MA). Analytical data of the synthesised com-
pounds are in agreement within ±0.4% of the theoretical values.
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TLC chromatography was performed using silica gel plates (Merck
F 254, Kenilworth, NJ), spots were visualised by UV light.
General procedure for the synthesis of compound derivatives
In a typical experiment, 0.0038mol of the appropriate
a,b-unsaturated ketone is dissolved in 30ml of boiling absolute
ethanol. On this solution, 10ml of a freshly prepared
hydroxylamine hydrochloride (0.0057mol) and potassium hydrox-
ide (0.013mol) water solution are added dropwise. The solution
becomes progressively orange and the reaction is monitored by
thin layer chromatography (TLC) (CH2Cl2/n-hexane: 20/1). By cool-
ing the reaction, the formation of a precipitate is observed which
was filtered and crystallised from ethanol.
By this procedure (Scheme 1), compounds EMAC II (i–m) were
synthesised.





Compound R Cryst. solvent Calc. Found M.P. (C) Yield % E.I. 70 eV mass spectra m/z (rel. ab.)
EMAC II i 4-Cl Ethanol 70.72, 5.19, 5.15 70.67, 5.17, 5.12 134-5 42 271 (100); 240 (78); 139 (17)
EMAC II j 4-CH3 Ethanol 81.24, 6.82, 5.57 81.27, 6.83, 5.54 103-4 46 251 (100); 220 (83); 119 (13)
EMAC II k 4-F Ethanol 75.28, 5.53, 5.49 75.31, 5.54, 5.43 132-4 41 255 (100); 224 (75); 123 (19)
EMAC II l 3,4-Cl Water/ethanol 62.76, 4.28, 4.57 62.72, 4.31, 4.54 134-5 65 305 (100); 274 (81); 173 (22)
EMAC II m 4-OCH3 ethanol 76.38, 6.41, 5.24 76.33, 6.40, 5.22 131-3 44 267 (100); 236 (71); 135 (9)
Figure 1. Scaffold evolution of MAO B inhibitors: from dihydro-pyrazoles to dihydro-isoxazoles.
Table 2. 1H NMR data and main fragments in E.I. mass spectrometry of derivatives EMAC II (i–m).
Compound 1H NMR d (ppm)
EMAC II i 1H-NMR: (300MHz, CDCl3) dH 2.38 (s, 3H, CH3), 3.23 (dd, 1H, Jab 16.5, Jax 7.8, CH2, isoxazole), 3.76 (dd, 1H, Jab 16.5, Jbx 10.1, CH2, isoxa-
zole), 5.59 (dd, 1H, Jbx 10.8, Jax 8.1, CH, isoxazole), 7.21 (d, 2H, J 7.8, CH, arom.), 7.33 (m, 4H, CH, arom.), 7.57 (2H, d, J 8.1, CH, arom.).
EMAC II j 1H-NMR: (300MHz, CDCl3) dH 2.37 (s, 3H, CH3), 2.43 (s, 3H, CH3), 3.30 (dd, 1H, Jab 16.5, Jax 8.3, CH2, isoxazole), 3.72 (dd, 1H, Jab 16.5, Jbx
10.8, CH2, isoxazole), 5.66 (dd, 1H, Jbx 10.8, Jax 8.3, CH, isoxazole), 7.16–7.29 (m, 6H, CH, arom.), 7.57 (d, 2H, J 8.3, CH, arom.).
EMAC II k 1H-NMR: (300MHz, CDCl3) dH 2.35 (s, 3H, CH3), 3.27 (dd, 1H, Jab 16.7, Jax 8.0, CH2, isoxazole), 3.74 (dd, 1H, Jab 16.5, Jbx 10.7, CH2, isoxa-
zole), 5.69 (dd, 1H, Jbx 10.7, Jax 8.3, CH, isoxazole), 7.04 (t, 2H, J 8.3, CH, arom.), 7.21 (d, 2H, J 8.1, CH, 4-CH3-phenyl), 7.36 (dd, 2H, CH,
J 8.3/5.3, arom.), 7.56 (d, 2H, J 8.2, CH, 4-CH3-phenyl).
EMAC II l 1H-NMR: (300MHz, CDCl3) dH 2.38 (s, 3H, CH3), 3.27 (dd, 1H, Jab 16.7, Jax 7.8, CH2, isoxazole), 3.78 (dd, 1H, Jab 16.4, Jbx 10.8, CH2, isoxa-
zole), 5.67 (dd, 1H, Jbx 10.8, Jax 7.8, CH, isoxazole), 7.21 (m, 3H, CH, arom.), 7.44 (d, 1H, J 8.2, CH, arom.), m, 7.49 (d, 1H, J 1.2, CH,
arom.), 7.56 (d, 2H, J 8.1, CH, arom.).
EMAC II m 1H-NMR: (300MHz, CDCl3) dH 2.38 (s, 3H, CH3), 3.30 (dd, 1H, Jab 16.7, Jax 7.8, CH2, isoxazole), 3.71 (dd, 1H, Jab 16.5, Jbx 10.6, CH2, isoxa-
zole), 3.80 (s, 3H, OCH3), 5.66 (dd, 1H, Jbx 10.5, Jax 8.6, CH, isoxazole), 6.89 (d, 2H, J 8.3, CH, arom.), 7.21 (d, 2H, J 8.2, CH, 4-CH3-phe-
nyl), 7.31 (d, 2H, J 8.7, CH, arom.), 7.58 (d, 2H, J 8.2, CH, 4-CH3-phenyl).
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HPLC enantioseparations and stereochemical characterisation
Direct separation of the enantiomers of EMAC II (i–m) was
achieved by HPLC using pure dichloromethane as the eluent. The
resolving power of the immobilized-type was sufficiently high to
achieve a baseline enantioseparation of all compounds in a short-
time analysis. The optimized analytical conditions were easily
scaled up to semipreparative level employing a 1 cm i.d. IA col-
umn. An amount of <20mg of racemic samples was resolved for
each chromatographic run, and both enantiomers were collected
with high enantiomeric purity. The stereochemical characterization
of compounds EMAC II (i–m) was performed by CD correlation
comparing the maximum and minimum of ellitipticity of the CD
spectra of the isolated enantiomers of compound EMAC II i of
known stereochemistry (Figure 2), as previously described by
some of us23. Single enantiomers were resubmitted to biological
assay.
Biological assay
The inhibitory activities of compounds EMAC II (i–m) on human
recombinant MAO A and B isoforms, expressed in baculovirus
infected BTI infected cells, as IC50, are reported in Table 1. Tested
compounds demonstrated no interference with the measurements,
since they were unable to directly react with the Amplex Red
reagent. The kinetic parameters of hMAO-A and hMAO-B were
evaluated in the presence of different tyramine concentrations. In
our experiments, hMAO-A displayed a Michaelis constant (Km) of
514 ± 46.8mM and a maximum reaction velocity (Vmax) of
301.4 ± 27.9 nmol/min/mg protein, whereas hMAO-B showed a Km
of 104.7 ± 16.3mM and a Vmax of 28.9 ± 6.3 nmol/min/mg protein
(n¼ 5). Active compounds showed reversible behaviour according
to the method proposed by Cer et al.24 Hence, reported IC50 is a
useful tool to determine the relative activity of the compounds
within the series as well as to determine substituent and key posi-
tions in the scaffold. All the tested compounds exhibited inhibitory
activity towards hMAO-B at nM concentration. Single enantiomers
activity was evaluated indicating that stereochemistry plays a rele-
vant role in determining inhibitory concentrations. None of the
tested compounds exhibited activity towards the A isoform of the
enzyme at the tested concentration of 100 mM.
Coordination studies
The interaction between EMAC II l and the Fe2þ or Fe3þ ions was
evaluated by recording the UV/VIS absorbance spectra of EMAC II
l (Figure 3) in absence and in presence either of FeCl3 or FeSO4.
EMAC II l was solubilised in DMSO then diluted to 1mM in
Figure 2. An ORTEP view of the molecular structure of (R)-()-EMAC II i enantiomer.
Scheme 1. Synthesis of EMAC II (i–m) compounds. Reagents and conditions: (i) ethanol, NaOH; (ii) ethanol, hydroxylamine hydrochloride, potassium hydroxide, reflux.
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50%DMSO solution. The UV/vis spectrum of the solution was
recorded before and after addition of 10mM final concentration
either of FeCl3 or FeSO4. The spectra were recorded with a
Ultrospec 2100 pro (Amersham Biosciences, Little Chalfont, UK)
and analysed with SWIFT II-METHOD software (GE Healthcare,
Little Chalfont, UK).
Molecular modelling studies
Protein preparation. Three-dimensional coordinates of the recep-
tor25 were obtained from the Protein Data Bank (PDB).26 The pro-
tein was processed and the internal hydrogen bonding network of
the receptor was optimized using the algorithm implemented in
Protein Preparation wizard.27
Ligand preparation. The ligands were built using Maestro GUI27.
The lowest energy conformer was considered for the subsequent
computational studies. This was obtained with MacroModel ver-
sion 7.228, considering MMFFs29 as force field and solvent effects
by adopting the implicit solvation model Generalized Born/Surface
Area (GB/SA) water30. The simulation was performed allowing
1000 steps Monte Carlo analysis with Polak-Ribier Conjugate
Gradient (PRCG) method and a convergence criterion of 0.05 kcal/
(mol Å).
Docking experiments. Previous reported and validated QMPL
docking protocol was applied using default settings21,31. In order
to better take into account the induced fit phenomena, the most
energy favoured generated complexes were fully optimized with
the AMBER united atoms force field32 in GB/SA implicit water,30
setting 5000 steps iterations analysis with PRCG method and a
convergence criterion of 0.1 kcal/(mol Å). Analysis of the results of
the complex minimization was carried out taking into account the
state equations (free energy of complex formation) computed at
300 K, applying molecular mechanics and continuum solvation
models with the molecular mechanics generalized Born33. The
resulting complexes were considered for the binding modes
graphical analysis with Pymol34 and Maestro27.
Results and discussion
Pursuing in our research on the design and synthesis of new
agents for the selective inhibition of MAO B, we have synthesised
a series of 3,5-diaryl-4,5-dihydro-isoxazoles EMAC II (i–m). All the
Figure 3. Effect of Fe2þ or Fe3þ ions on the spectrum of absorbance of EMAC II l. UV/vis spectrum was measured with 100lM of compound alone (unbroken line) or
in the presence of 10mM FeCl3 or FeSO4 (dotted line).
Table 3. Inhibitory activities towards hMAO-A and hMAO-B of EMAC II (i–m) derivatives.






















b 449.57 ± 18.02 nM >222d
Clorgiline 4.46 ± 0.32 nMc 61.35 ± 1.13lM 0.000073
L-Deprenyl 67.25 ± 1.02lMc 19.60 ± 0.86 nM 3431.12
Iproniazide 6.56 ± 0.76lM 7.54 ± 0.36lM 0.87
Moclobemide 361.38 ± 19.37 lM a <0.36e
aInactive at 1mM (highest concentration tested).
bInactive at 100 lM (highest concentration tested). At higher concentration, the compounds precipitate.
cResults are mean ± SEM from five experiments. Level of statistical significance: cP <0.01 versus the corresponding IC50 values obtained against MAO-B, as determined
by ANOVA/Dunnett’s.
dValues obtained under the assumption that the corresponding IC50 against MAO-A is the highest concentration tested (100lM).
eSelectivity ratios [IC50(MAO-A)]/[IC50(MAO-B)].
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compounds were submitted to biological evaluation to investigate
their ability to inhibit both MAO isoforms. The structure and the
MAO A and MAO B IC50 values and selectivity ratios of the new
derivatives are reported in Table 3. All the compounds inhibit
MAO B isozyme with IC50 values ranging from higher to lower
nanomolar range. Accordingly to what is observed in our previous
report on similar derivatives21, compound EMAC II l, bearing a
3,4-dichlorophenyl moiety in the position 5 of the dihydro-
isoxazole ring resulted, the most active within all the tested
compounds. Based on this observation we assumed that, in the
formation of the enzyme–ligand complex, this portion of the
inhibitor is, in all probability, oriented similarly with respect to our
previously reported compounds. Interestingly, none of the new
compounds exhibited activity towards the MAO A isoform of the
enzyme up to 100 mM concentration. Considering the presence of
an asymmetric carbon at the position 5 of the dihydro-isoxazole
nucleus we performed, semipreparative chromatographic enantio-
separation of all the new derivatives EMAC II (i–m). The separated
enantiomers were then submitted to biological evaluation (Table
4). The obtained data pointed out the importance of enantiomeric
separation for both potency and selectivity. In particular, in the
case of compound R-()-EMAC II l, the IC50 value towards MAO B,
drops from 11.97 nM to 1.89 nM, while the selectivity towards
MAO B is increased by more than six folds. Moreover, considering
the growing interest in the development of iron chelators for the
treatment of neurodegenerative disorders35–37, we have prelimin-
arily investigated our best compound able to bind iron II and iron
III cations following a previously reported procedure38. According
to our preliminary results (Figure 3), compound EMAC II l do not
have the ability to bind neither iron II nor iron III cations.
In order to explore the nature of the ligand–receptor interac-
tions, we have carried out docking experiments considering the
MAO B active site by means of QMPL docking protocol31,39,40. We
have focused our attention on the most active compound R-
()-EMAC II l, which shows the lowest IC50 value and the highest
selectivity towards MAO-B.
It should be pointed out that MAO-B cavity is rather narrow,
therefore, small changes are reflected in the biological activity. In
this respect, the best compound shows remarkable difference of
activity between the R and the S enantiomers. An analogous
behaviour was observed in the previous series11,20. According to
docking and post docking best scored pose, the most stable com-
plex configurations of both R and S enantiomers are depicted in
Figure 4(a,b).
Table 4. Inhibitory activities towards hMAO-A and hMAO-B of EMAC II (i–m) sin-
gle enantiomers.
Compound MAO-A (IC50) MAO-B (IC50) Ratio
R-(2) EMAC II i a 15.27 ± 0.95 nM 6549b
S-(1) EMAC II i a a
R-(2) EMAC II j a 2.55 ± 0.11 nM 39 216b
S-(1) EMAC II j a 31.37 ± 1.67 lM 3188b
R-(2) EMAC II k a 299.86 ± 12.04 nM 333.5b
S-(1) EMAC II k a 33.82 ± 1.12 lM 2956b
R-(2) EMAC II l a 1.89 ± 0.16 nM 52 910b
S-(1) EMAC II l a 10.96 ± 0.83 lM 9124
R-(2) EMAC II m a 126.16 ± 8.44 nM 792.6b
S-(1) EMAC II m a 291.82 ± 13.45 nM 342.6
IC50 values are the mean ± SEM from five experiments.
aInactive at 100lM (highest concentration tested).
bValues obtained under the assumption that the corresponding IC50 against
MAO-B is the highest concentration tested (100 lM).
Figure 4. Putative binding mode of compound EMAC II l. (a) R-()-EMAC II l/MAO-B complex; (c) S-(1)-EMAC II l/MAO-B complex; (b, d) compound 2D representation and
binding pocket interacting residues: green, hydrophobic; cyan, polar residues. Green arrows indicate pp interactions.
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The R enantiomer is stabilized by pp interactions with Trp119,
Phe103, Phe343, Tyr326 and some hydrophobic interactions with
several residues in the binding pocket: Leu 164, Leu 167, Phe 168,
Ile 316, Ile 199, Ile198, Leu 171 and the Tyr of the aromatic cage
435, 298, 188.
Conversely, the S enantiomer is oriented in the opposite way:
with the dichlorophenyl substituent in the entrance cavity and the
4-methylphenyl substituent in the catalytic cavity toward the FAD.
The complex results in less stability and gives rise only to a single
pp interaction with Tyr 435 and several hydrophobic interactions
(Figure 4(c,d)).
Compared with previous series21, the absence of acetyl group
allows a better accommodation in the cavity (Figures 4(a) and
5(a)). Once again, the importance in crossing both entrance and
catalytic cavity, in order to achieve the MAO-B isoform selective
activity is confirmed. This essential requisite has been reported by
several studies25,41,42 and can be observed in co-crystallized select-
ive MAO B inhibitors. A typical example is the inhibitor safinamide
(Figure 5(c,d))25,43.
Conclusions
In summary, a small library of 3,5-diaryl-4,5-dihydroisoxazoles have
been designed and synthesized on the basis of previously
reported MAO inhibitors. Our finding highlighted the capability of
3,5-diaryl-4,5-dihydroisoxazoles to exert specific recognition and
inhibition against the isoform B of MAO. The stereochemical char-
acterization of R/S enantiomers confirms an enantioselective effect
against MAO B isoform. This scaffold is definitively interesting for
the development of novel selective neuroprotective agents.
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